Iconovo receives a US patent for ICOcap® that strengthens the offering for more customer collaborations
Iconovo AB (publ), which develops complete inhalation products for a global market, announces today that the U.S. Patent and Trademark Office has approved the company's application for design protection of the ICOcap® inhaler. Iconovo recently regained the global rights to sell and distribute ICOcap® from Stevanato Group and intends to intensify the marketing of the inhaler towards international pharmaceutical companies, while Stevanato Group will act as the exclusive contract manufacturer.
The design protection that the US Patent and Trademark Office has now issued for ICOcap® is valid until May 2037. The inhaler is already protected by patents in Europe. ICOcap® is one of several inhaler platforms that form the basis of Iconovo's customer offering in contract development management (CDMO). Earlier this year, a collaboration project was initiated with Kiox Pharma to develop a new treatment based on ICOcap® for a rare but serious lung disease.
"The fact that we have obtained strong exclusivity protection for ICOcap® in the world's largest pharmaceutical market further strengthens the offering for generating additional collaborative projects with international customers based on our unique inhaler. In addition, it broadens the opportunities for direct sales of the inhalers", says Roger Lassing, Vice President Business Development at Iconovo.
ICOcap® is a patented capsule-based dry powder inhaler with a one-piece-design making it easy to use. It has a robust, unique easy-to-grip design, a patented integrated mouthpiece cover, and low inhalation resistance. A standard version of ICOcap® is available off-the-shelf with the same function and performance as the established inhalers Breezhaler® from Novartis and RS01 from Berry.
Redwood Pharma AB meddelar sista dag för handel med BTU och första dag för handel med teckningsoptioner av serie TO 5
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I USA, AUSTRALIEN, JAPAN, KANADA, NYA ZEELAND, SYDAFRIKA, HONGKONG, SCHWEIZ, SINGAPORE, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...
Valberedning utsedd i Promimic AB (publ)
Utnämningen har skett i enlighet med den instruktion avseende principer för utseende till Valberedning som fastställdes vid årsstämman i Promimic AB den 25 april 2023. De aktieägare som har utsett ledamöterna i valberedningen representerade sammanlagt drygt 70 % a...
ExpreS2ion announces changes to leadership team
Hørsholm, Denmark, 27 September 2023 - ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”), a pioneer in the development of innovative vaccines for a healthier world, today announced that Dr. Mattis Ranthe, Chief Medical Officer, and Dr. Mette Thorn, Senior Vice President of Preclinical De...